198 related articles for article (PubMed ID: 33998886)
1. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
[No Abstract] [Full Text] [Related]
2. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
Smith KE; Staton M
Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
[No Abstract] [Full Text] [Related]
3. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
[TBL] [Abstract][Full Text] [Related]
4. Can cannabis kill? Characteristics of deaths following cannabis use in England (1998-2020).
Rock KL; Englund A; Morley S; Rice K; Copeland CS
J Psychopharmacol; 2022 Dec; 36(12):1362-1370. PubMed ID: 35946604
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
[TBL] [Abstract][Full Text] [Related]
6. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
[TBL] [Abstract][Full Text] [Related]
7. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
[TBL] [Abstract][Full Text] [Related]
8. Drug-related deaths associated with vaping product use in the United Kingdom.
Roberts E; Copeland C; Robson D; McNeill A
Addiction; 2021 Oct; 116(10):2908-2911. PubMed ID: 33751729
[TBL] [Abstract][Full Text] [Related]
9. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
[TBL] [Abstract][Full Text] [Related]
10. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
Santangelo O; Baldwin JM; Stogner J
Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
[TBL] [Abstract][Full Text] [Related]
11. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
[TBL] [Abstract][Full Text] [Related]
12. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
[TBL] [Abstract][Full Text] [Related]
13. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.
McQuade D; Hudson S; Dargan PI; Wood DM
Eur J Clin Pharmacol; 2013 Mar; 69(3):373-6. PubMed ID: 22936123
[TBL] [Abstract][Full Text] [Related]
14. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
Cairns R; Brown JA; Gunja N; Buckley NA
Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
[TBL] [Abstract][Full Text] [Related]
15. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Cannabinoid Receptor Agonists in Postmortem Casework in Scotland.
Seywright A; Irvine AFD; McKeown DA; Wylie FM; Torrance HJ
J Anal Toxicol; 2023 Jan; 46(9):1066-1072. PubMed ID: 34994788
[TBL] [Abstract][Full Text] [Related]
17. Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.
Craft S; Dunn M; Vidler D; Officer J; Blagbrough IS; Pudney CR; Henderson G; Abouzeid A; Dargan PI; Eddleston M; Cooper J; Hill SL; Roper C; Freeman TP; Thomas SHL
Addiction; 2022 Nov; 117(11):2899-2906. PubMed ID: 35665553
[TBL] [Abstract][Full Text] [Related]
18. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market.
Norman C; Walker G; McKirdy B; McDonald C; Fletcher D; Antonides LH; Sutcliffe OB; Nic Daéid N; McKenzie C
Drug Test Anal; 2020 Apr; 12(4):538-554. PubMed ID: 31944624
[TBL] [Abstract][Full Text] [Related]
19. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
Zaurova M; Hoffman RS; Vlahov D; Manini AF
J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
[TBL] [Abstract][Full Text] [Related]
20. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
King A; Hill SL; Pucci M; Bailey G; Keating L; Macfarlane R; Cantle F; Hudson S; Thomas SHL
Clin Toxicol (Phila); 2022 Oct; 60(10):1094-1098. PubMed ID: 35943421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
